帕利哌酮缓释片治疗精神分裂症44例疗效及安全性临床观察  

The clinical efficacy of paliperidone in the treatment of schizophrenia

作　　者：李裕基[1] 张宏久[1] 刘文英[1] 高欢[1] 

机构地区：[1]广东省深圳市康宁医院,广东深圳518020

出　　处：《中国民康医学》2011年第9期1114-1115,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:评价帕利哌酮缓释片治疗首发或复发精神分裂症的疗效和安全性。方法:用帕利哌酮缓释片治疗首发和复发精神分裂症共44例,疗程8周,用阳性症状和阴性症状量表(PANSS)和副反应量表(TESS)评定疗效及不良反应。结果:完成8周治疗的44例首发和复发精神分裂症患者的疗效为:痊愈21例(47.8%)、显著进步13例(29.5%)、进步6例(13.6%)、无效4例(9.1%),总有效率为90.9%;不良反应轻微。结论:帕利哌酮缓释片治疗精神分裂症临床疗效较好,安全性较高,依从性较佳,值得在临床一线广泛应用。Objective：To determine the clinical efficacy and safety of paliperidone in the treatment of schizophrenia.Methods：44 patients with first episode schizophrenia were treated with olanzapine for 8 weeks,and assessed with PANSS and TESS for the efficacy and safety.Results： 44 cases who completed the 8 weeks treatment,21 cases（47.8%） were cured,13 cases（29.5%）were significantly improved,6cases（13.6%）improved and 4 cases（9.1%）had no response.Total effective rate was 90.9%,with effect and mild obvious side effect.Conclusions： The study suggests that paliperidone is a safe,effective agent in the treatment of schizophrenia.

关 键 词：帕利哌酮缓释片 精神分裂症 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]